Clinical Research Directory

Inclusion Criteria: * Has signed a written informed consent form and voluntarily participates in this study; * Age: 18-75 years old, regardless of gender; * Histologically or cytologically confirmed colorectal adenocarcinoma with liver metastases, initially unresectable but potentially resectable as assessed by a multidisciplinary team (MDT), without other definite extrahepatic distant metastases; * No prior systemic treatment; * Known RAS and BRAF status; * No contraindications to liver surgery; * At least one measurable lesion according to RECIST 1.1; * ECOG performance status: 0-1; * Expected survival time \> 12 weeks; * Sufficient organ and bone marrow function. Exclusion Criteria: * Active autoimmune diseases requiring systemic treatment occurring within 2 years before enrollment. * Previous receipt of immune checkpoint inhibitors, including: anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, etc. * Previous receipt of targeted drugs targeting epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), or their receptors (VEGFR), including bevacizumab, cetuximab, panitumumab, aflibercept, regorafenib, anlotinib, etc. * Definite extrahepatic distant metastatic lesions. * Unresectable primary tumor. * HIV infection, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or allogeneic bone marrow transplantation (except corneal transplantation). * Previous or concurrent other malignant tumors within 5 years; * Accompanying pleural effusion, pericardial effusion, or ascites that is uncontrollable and requires drainage. * Known active pulmonary tuberculosis, radiation pneumonitis, drug-induced pneumonia, or other diseases, symptoms, or signs causing severe impairment of lung function.